INCLISIRAN (Leqvio®)

Clinical Indication

Treating primary hypercholesterolaemia or mixed dyslipidaemia. SECONDARY PREVENTION ONLY as per NICE TA733

Comments

For prescribers who feel competent to use this medication.

In line with NICE TA733.

The AAC Lipid management pathway gives further guidance on place in therapy and the AHSN have some inclisiran FAQS. Please see the Cardiovascular Guideline page

Date of classification

February 2022

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.